Companies › Shanghai Ark Biopharmaceutical
3 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Other, Infectious disease; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ziresovir (AK0529) Fusion glycoprotein F0 inhibitor | – | Phase 3 | Respiratory Synctial Virus Infections; Respiratory Syncytial Virus Infections | Dec 2028 |
| AK0406 | – | Phase 1 | Healthy Participants | Apr 2027 |
| AK0610 | – | Phase 1 | Healthy Volunteer Study | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06775405 | Ziresovir (AK0529) | Phase 3 | Respiratory Synctial Virus Infections | Infectious disease | Apr 2025 |
| NCT06996704 | AK0610 | Phase 1 | Healthy Volunteer Study | Other | May 2025 |
| NCT07432698 | AK0406 | Phase 1 | Healthy Participants | Other | Apr 2027 |
| NCT07658534 | Ziresovir (AK0529) | Phase 2 | Respiratory Syncytial Virus Infections | Infectious disease | Dec 2028 |
No annotated target.
–
Atea Pharmaceuticals Basilea Pharmaceutica Tortugas Neuroscience BioAegis Therapeutics Ensysce Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.